Evidence map›Paper›PMID 38500034›Full record

ArticleBMC genomics2024

Generalizability of machine learning in predicting antimicrobial resistance in E. coli: a multi-country case study in Africa.

Mike Nsubuga, Ronald Galiwango, Daudi Jjingo, Gerald Mboowa

Abstract read
In one paragraph

Article in BMC genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. How AI can help us beat AMR.npj antimicrobials and resistance · 2025
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mike NsubugaDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, P.O Box 7072, Kampala, Uganda.
Ronald GaliwangoDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, P.O Box 7072, Kampala, Uganda.
Daudi JjingoDepartment of Computer Science, College of Computing and Information Sciences, Makerere University, P.O Box 7062, Kampala, Uganda.
Gerald MboowaDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, P.O Box 7072, Kampala, Uganda. gmboowa@gmail.com.

Funding

Makerere University Data Science Research Training to Strengthen Evidence-Based Health Innovation, Intervention and Policy (MakDARTA)U2RTW012116 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI William Checkley, Moses Lutaakome Joloba · 2021 to 2026
$2.0M
Eastern Africa Network for Bioinformatics Training - (EANBiT)U2RTW010677 · FIC · INTERNATIONAL CENTRE OF INSECT PHYSIOLOG · PI MASIGA, DANIEL KANANI · 2017 to 2022
$1.2M
FIC NIH HHS U2R TW010677FIC NIH HHS U2R TW012116
6 · The paper itself

Abstract

backgroundAntimicrobial resistance (AMR) remains a significant global health threat particularly impacting low- and middle-income countries (LMICs). These regions often grapple with limited healthcare resources and access to advanced diagnostic tools. Consequently, there is a pressing need for innovative approaches that can enhance AMR surveillance and management. Machine learning (ML) though underutilized in these settings, presents a promising avenue. This study leverages ML models trained on whole-genome sequencing data from England, where such data is more readily available, to predict AMR in E. coli, targeting key antibiotics such as ciprofloxacin, ampicillin, and cefotaxime. A crucial part of our work involved the validation of these models using an independent dataset from Africa, specifically from Uganda, Nigeria, and Tanzania, to ascertain their applicability and effectiveness in LMICs.

resultsModel performance varied across antibiotics. The Support Vector Machine excelled in predicting ciprofloxacin resistance (87% accuracy, F1 Score: 0.57), Light Gradient Boosting Machine for cefotaxime (92% accuracy, F1 Score: 0.42), and Gradient Boosting for ampicillin (58% accuracy, F1 Score: 0.66). In validation with data from Africa, Logistic Regression showed high accuracy for ampicillin (94%, F1 Score: 0.97), while Random Forest and Light Gradient Boosting Machine were effective for ciprofloxacin (50% accuracy, F1 Score: 0.56) and cefotaxime (45% accuracy, F1 Score:0.54), respectively. Key mutations associated with AMR were identified for these antibiotics.

conclusionAs the threat of AMR continues to rise, the successful application of these models, particularly on genomic datasets from LMICs, signals a promising avenue for improving AMR prediction to support large AMR surveillance programs. This work thus not only expands our current understanding of the genetic underpinnings of AMR but also provides a robust methodological framework that can guide future research and applications in the fight against AMR.

Indexed as

Anti-Bacterial AgentsEscherichia coliAmpicillinCefotaximeCiprofloxacinDrug Resistance, BacterialMachine LearningNigeriaAmpicillinAnti-Bacterial AgentsCefotaximeCiprofloxacinAfricaAntimicrobial resistanceE. coliMachine learningWhole-genome sequencing

Identifiers

PMID38500034
PMCPMC10946178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.